Abstract:Background: Immune-related colitis is a common, often serious complication of immune checkpoint inhibition (ICI). Although endoscopy is not strictly recommended for any grade of diarrhea/colitis, emerging evidence suggests that endoscopic evaluation may have important therapeutic implications. In this retrospective study, we sought to comprehensively characterize the clinical and histologic features of ICI-induced colitis with a specific focus on evaluating the prognostic role of endoscopy. Methods: Data were collected from the medical records of 130 patients with confirmed ICI-induced colitis. In a subset of patients (n=44) with endoscopic and pathologic data, endoscopic data were scored using the Mayo Endoscopic Score (MES) with scores ranging from 0 (no inflammation) to 3 (colonic ulceration). The impact of infliximab on antitumor outcomes was evaluated using progression-free survival (PFS) and overall survival (OS). Results: We identified 130 patients with ICI-induced colitis across two institutions. All patients were treated with corticosteroids. Additional and/or alternative immunosuppression was employed in 59 cases, with 52 patients (42%) requiring at least one infusion of infliximab 5 mg/kg. Endoscopic assessment with biopsy was performed in 123 cases of suspected colitis (95%), with 44 cases available for MES tabulation. Presence of ulceration (MES 3) was associated with use of infliximab (p=0.008) and MES was significantly higher in patients who received infliximab compared with those who did not (p=0.003) with a median score of 2.5; conversely, those with an MES of zero rarely required secondary immunosuppression. Notably, symptoms of colitis based on Common Terminology Criteria for Adverse Events grade had no association with endoscopic findings based on MES classification. After adjustment for baseline patient and disease characteristics, there was no significant difference in steroid duration or cancer-related outcomes in patients treated with infliximab. Conclusions: In our study, we demonstrate the association of endoscopic features, specifically the MES, with immunosuppressive needs. Importantly, we also show that MES was not related to severity of patient symptoms. The data suggest that endoscopic features can guide clinical decision-making better than patient symptoms, both identifying high-risk patients who will require infliximab and those who are likely to respond to initial corticosteroids.

S2970 Treatment of Immune Checkpoint Inhibitor Induced Sclerosing Mesenteritis: A Case Series

S1271 A Retrospective Study of Treatment Options for Checkpoint-Inhibitor Colitis and Their Impact on Disease Outcomes

Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment

S3034 Refractory Immune Checkpoint Inhibitor-Associated Colitis: Case Report

Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics

Immune-mediated Colitis from Dual Checkpoint Inhibitors.

S1303 Initial Histologic Presentations of Immune Checkpoint Inhibitor Colitis and Their Differential Disease Outcomes

Severe Immune-Mediated Colitis Induced by Checkpoint Inhibitors in an Adolescent With Lynch Syndrome

Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosis

S1487 Multiple Gastrointestinal Immune Related Adverse Events From Immune Checkpoint Inhibitor Therapy

Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report

Immune checkpoint blockade induced sarcoid-like reaction mimicking progression of disease in a patient with microsatellite instable colorectal cancer: case report and review of the literature

S2230 Risk Factors, Clinical Features and Diagnostic Workup of Sclerosing Mesenteritis: A Single-Center Retrospective Study of 222 Patients

Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn’s disease: A case report

A Case of Immune Checkpoint Inhibitor-Induced Probable Myocarditis and Treatment Response

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events

Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors

S4410 Mycophenolate - A Treatment Option in Steroid Refractory Hepatitis Associated With Immune Checkpoint Inhibitors

Immune checkpoint inhibitor therapy associated enteritis mimicking celiac disease

Gut microbiota shifts from onset to remission in immune checkpoint inhibitor-induced enterocolitis: a case report

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis